Cyclic phosphatidic acid (cPA) is found in cells from slime mold to humans and has a largely unknown function. We previously reported that cPA significantly inhibited the lipid accumulation in 3T3-L1 adipocytes through inhibition of PPARc activation. We find here that cPA reduced intracellular triglyceride levels and inhibited the phosphodiesterase 3B (PDE3B) expression in 3T3-L1 adipocytes. PPARc activation in adipogenesis that can be blocked by treatment with cPA then participates in adipocyte function through inhibition of PDE3B expression. We also found the intracellular cAMP levels in 3T3-L1 adipocytes increased after exposure to cPA. These findings contribute to the participation of cPA on the lipolytic activity in 3T3-L1 adipocytes. Our studies imply that cPA might be a therapeutic compound in the treatment of obesity and obesity-related diseases.
Introduction
Overweight and obesity are worldwide health problems. There are more than 1 billion overweight adults in the world, and there are at least 300 million clinically obese people [1] . Obesity is a condition in which adipocytes accumulate a large amount of body fat and become enlarged. Adipocytes play a critical role in lipid homeostasis and energy balance. Adipose differentiation is a complex process by which fibroblast-like undifferentiated cells are converted into cells that accumulate lipid droplets [2] . It has been reported that PPARc plays a critical role in adipogenesis [2, 3] . PPARc is a nuclear hormone receptor that plays an essential role in lipid and glucose homeostasis and predominantly expressed in the adipose tissue [2] . Upon agonist binding, PPARc drives the expression of several adipocyte-specific genes [3] such as FABP4 (fatty acid binding protein 4) and CD36 (scavenger receptor). PPARc agonists are known to induce the differentiation of preadipocytes into mature adipocyte. Physiological agonists include 15d-PGJ 2 [4] , lysophospholipids, such as lysophosphatidic acid (LPA) [5] and alkyl glycerophosphate (AGP) [6] , oxidized phospholipids [7] and nitrated fatty acids [8] . The thiazolidinediones agonists, including rosiglitazone and pioglitazone are widely used in type II diabetes mellitus to improve insulin sensitivity by inducing the expression of genes involved in adipocyte differentiation, lipid and glucose uptake, and fatty acid storage [9] [10] [11] . Furthermore, PPARc activation is also known to be necessary and sufficient for neointimal lesion formation [12] . Neointima formation is an early step in the development of atherosclerotic plaques [13, 14] . Atherogenic lesions progress through a prolonged process of lipid accumulation and can trigger ischemic attack or stroke [15] . Recent studies indicate that PPARc antagonists are able to inhibit adipocyte differentiation. The bisphenol A diglycidyl ether (BADGE) has been shown to possess both agonist and antagonist activities toward PPARc, and to block the ability of adipogenic cell lines such as 3T3-L1 and 3T3-F442A cells [16] . T0070907 was identified as a potent and selective PPARc antagonist and it also inhibited lipid accumulation in 3T3-L1 cells [17] . We have been reported that cPA is a specific and high-affinity antagonist of PPARc [18] [19] [20] . cPA is a naturally occurring analog of LPA in which the sn-2 hydroxy group forms a 5-membered ring with the sn-3 phosphate [21] [22] [23] . cPA is generated by transphosphatidylation of lysophosphatidyl choline (LPC) catalyzed by phospholipase D [24] .
In 3T3-L1 adipocytes, investigations on PDE have focused on hormone-sensitive PDE3B activity and its expression [25, 26] . PDE3B is found in adipocytes and pancreatic b-cells [25, 27] , and levels of PDE3B mRNA and protein are lower in white adipose tissue of rodents model [28] . Furthermore, decreases in PDE3B activity is accompanied by increases in intracellular cAMP that in turn lead to the activation of cAMP-dependent protein kinase A (PKA). This then leads to the activation of hormone-sensitive lipase (HSL), subsequently to an increase in the stored TG hydrolysis rate, and finally to increases in the release of FFA and glycerol from adipocytes. In this article, we report show that the PPARc antagonist cPA inhibits differentiation of adipocyte, downregulation of PDE3B expression, increase of intracellular cAMP production, and stimulated lipolysis activity in 3T3-L1 adipocytes.
Materials and methods

Reagents and antibodies
Cyclic phosphatidic acid (16:0) was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Carba cyclic phosphatidic acids, 3ccPA and 2ccPA, were chemically synthesized according to Uchiyama et al. [29] . Purity of cPA or ccPA were confirmed by TLC and negative ion liquid chromatography-mass spectrometry (data not shown). Rosiglitazone was purchased from ALEXIS Biochemicals (Lausen, Switzerland) and prepared as a 10 mM stock in ethanol. T0070907 was purchased from Cayman chemical company (Ann Arbor, Michigan, USA). GW9662, 3-isobutyl-1-methylxanthine (IBMX), dexamethasone, cilostazol and insulin (from bovine pancreas) were purchased from Sigma Aldrich (St. Louis, MO, USA). PDE inhibitors (for PDE1, PDE2 and PDE4), anti-PPARc antibody (sc-7196), anti-PDE3B antibody (sc-20793) and anti-b-actin antibody (sc-47778) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Cell culture
Murine 3T3-L1 cells were purchased from American Type Culture Collection (VA, USA) and cultured in Dulbecco's modified Eagle's medium supplemented with fetal calf serum and antibiotics. Adipocyte differentiation of 3T3-L1 cells was induced by incubation of the cells for 2 days in differentiation medium supplement with insulin (10 lg/ml), 1 lM dexamethasone, and 500 lM IBMX.
On day 2, the medium was replaced with growth medium containing insulin (10 lg/ml) alone and changed every 2 days. Adipocytes were used for experiments 7-10 days after initiating differentiation.
Cell viability assay
Trypan blue dye exclusion method is used to determine the number of viable cells present in a cell suspension using hemocytometer.
Oil-red O staining
The extent of differentiation was determined by the amount of lipid accumulation at 10 days by Lipid Staining Kit (Zen-Bio, Inc., NC, USA). Briefly, cells were fixed in fixative solution for 1 h and then stained with 0.6% oil-red O solution in isopropyl alcohol/ H 2 O (60:40, v/v) for 1 h at room temperature, washed four times with distilled water, and dried. Differentiation was examined by visual inspection and quantified by elution with isopropyl alcohol and an optical density measurement at 590 nm (Beckman DU-640).
Reporter gene assay
To determine endogenous PPARc activation, 3T3-L1 cells were co-transfected with pGL3b-PPRE (ACO)-Fluc and pSV40-b-galactosidase plasmids and subjected to the reporter gene assay as described before. Twenty-four hours after transfection, cells were treated with indicated compounds and cultured for an additional 20 h. Luciferase activity was measured with the Steady-Glo luciferase Assay System (Promega, WI, USA) using the SpectraMax plate reader (Molecular Devices, CA, USA).
Lipolysis assay
Lypolysis was measured as glycerol release an adipocyte suspension by Lipolysis Assay Kit (Zen-Bio, Inc., Research Triangle Park, NC, USA). 3T3-L1 cells are plated in 96 well plates and allowed to differentiate under the standard differentiation condition for 1 week. Confluent monolayers of adipocytes were washed with PBS and exposed to PDE inhibitors (5 lM each) or cPA (0.1-30 lM)
or vehicle in phenol red-free DMEM with 2% fatty acid-free BSA for up to 18 h at 37°C in 5% CO 2 incubator. Cells were then washed with cold PBS and lysed in 1% Triton X-100 buffer, and the protein concentration was determined and used to normalize glycerol release. Culture supernatants were collected and analyzed for glycerol, a breakdown product of TG.
Quantitative real-time PCR analysis
Total RNA was prepared using TRIzol reagent (Invitrogen, CA, USA) from 3T3-L1 (2 Â 10 5 cell). One microgram of total RNA was used for the subsequent synthesis of cDNA using the First-Strand Synthesis kit (Promega, Madison, WI, USA) as recommended by the manufacturer. Quantification of mRNA levels was measured by using a real-time PCR system (Applied Biosystems, CA, USA) and First Start Universal SYBR Green PCR Master (Roche Applied Science, Germany) with the following primer pair sets: PDE3B,
0 -CTGCACCACCAACTGCTTAG (F) and 5 0 -GGGCCATCCAC AGTCTTCT-3 0 (R).
Western blot analysis
Cells were washed twice with ice-cold PBS and solubilized with whole-cell extraction buffer (20 mM HEPES (pH 7.9), 0.5% NP-40, 15% glycerol, 300 mM NaCl, 1 mM EDTA, 10 mM NaF, 1 mM Na 3 VO 4 , 1 mM DTT, 1 lg/ml leupeptin, 1 lg/ml pepstatin, 1 lg/ ml aprotinin and 0.5 mM PMSF). The cell lysate was centrifuged at 14,000g for 5 min, and the protein in the supernatant was quantified using Bradford protein assay reagent (Bio-Rad, CA, USA). Total protein was diluted 1:4 with lane marker reducing sample buffer (ThermoFisher Scientific, MA, USA) and boiled for 5 min. The resultant protein was then separated on 10% SDS-PAGE and transferred onto a PVDF membrane (GE Healthcare, NJ, USA). The membrane was blocked by 5% skim milk in TBS (Tris-buffered saline) with 0.1% Tween 20 (pH 7.6) for 1 h at room temperature and probed with primary rabbit anti-human PDE3B and actin antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) at 4°C overnight. After washing, the membrane was incubated with secondary antirabbit antibody for 1 h at room temperature and then developed with ECL-plus chemiluminescent detection reagent (GE Healthcare, Piscataway, NJ, USA).
Effect of cPA on intracellular cAMP level
The differentiated 3T3-L1 cells were incubated in medium containing cPA for 6 h. cAMP levels in cell extracts were measured by ELISA (cAMP Biotrak Enzyme immunoassay system, Amersham Biosciences) in 96-well plates on a spectrophotometer at 450 nm according to the manufacturer's instructions.
Results and discussion
cPA is an adipogenic antagonist through PPARc inhibition
As mentioned above, we have described that cPA (Fig. 1A) inhibited the lipid accumulation in 3T3-L1 adipocytes. To confirm our previous observations, we designed and performed more detailed studies. As shown in Fig. 1B , a viability assay was used to determine any possible adverse effects of cPA. The viability of cultured 3T3-L1 cells was not affected by incubation in differentiation buffer with various concentration of cPA (up to 10 lV). PPARc is a master regulator in the formation of fat cell, and two PPARc isoforms (PPARc1 and PPARc2) have been found in adipocytes [2] . We examined the expression level of PPARc in 3T3-L1 cells using Western blot analysis. The expression of PPARc2 protein in 3T3-L1 cells increased accompanying by the differentiation to adipocyte after addition of differentiation buffer (Fig. 1C) . We then investigated whether cPA could block the induction of adipogenesis in 3T3-L1 cells. As shown in Fig. 1D and E, the standard differentiation treatment with dexamethasone, IBMX, and insulin promoted lipid accumulation in 3T3-L1 cells. In contrast, lipid accumulation in these cells was obviously inhibited when cells were treated with both cPA and the differentiation mixture. These results suggest that significant reduction in lipid accumulation is not due to toxic side effect by cPA. The synthetic PPARc antagonists, such as T0070907 and GW9662 have also exhibited strong inhibitory effects of adipogenesis. To confirm the (E) Oil red O was eluted by 2-propanol and quantified at 490 nm (mean ± SEM n = 3, **p < 0.01 based on Student's t-test). DB: differentiation buffer.
PPARc receptor in 3T3-L1 cells is functional, we transfected the cells with a luciferase reporter plasmid. Following treatment of cell lines with differentiation buffer, cPA and T0070907 inhibited the PPARc activation elicited by rosiglitazone ( Fig. 2A) . These data suggest that cPA inhibits the PPARc-dependent transcriptional responses in 3T3-L1 adipocytes. PPARc agonists are known to promote the conversion of a variety of preadipocyte into mature adipocyte [30] . Incubation of 3T3-L1 cells with 1 lV rosiglitazone for 7 days resulted in their efficient conversion to adipocytes (Fig. 2B) , as indicated by the increase in Oil-red O staining (Fig. 2C ) and the induction of adipocyte specific gene, FABP4 and CD36 (Fig. 2D) . In contrast, when the cells were cotreated with 10 lV cPA, a significant conversion to the adipocyte phenotype was not observed. Thus, cPA is proposed to be a potent antagonist of adipocyte differentiation in 3T3-L1 cells.
Effect of cPA on PDE3B mRNA and protein expression in 3T3-L1 adipocytes
As it remains a matter of debate how cPA mediates its function on the regulation of adipogenesis. We assess the ability of selective PDE inhibitors to induce lipolysis in 3T3-L1 adipocytes. PDE is a key enzyme involved in the anti-lipolytic action and PDE activation results in a reduced intracellular cAMP level [31] . It has been reported that the main type of PDE expressed in insulin-sensitive cells, such as adipocytes, is PDE3B [32] . As shown in Fig. 2E , inhibition of PDE3 with specific inhibitor, cilostazol (5 lV) activated glycerol release from 3T3-L1 adipocytes. In contrast, each inhibitors for PDE1 (8-Methoxymethyl-IBMX), PDE2 (EHNA) and PDE4 (Rolipram) (5 lV each) did not significantly stimulated lipolysis in 3T3-L1 adipocytes. These observations led us to assume that PDE3 inhibitors are capable of inducing degradation of TG to glycerol and FFA in 3T3-L1 adipocytes. It was reported that the downregulation of PDE3B gene expression correlated with the decrease in PDE3B protein expression and activity in white adipose tissue of animal model for type II diabetes [28] . We then performed the effect of cPA on the expression level of PDE3B mRNA in 3T3-L1 adipocytes on the day 7 after induction. Interestingly, PPARc agonist, rosiglitazone significantly up-regulated PDE3B gene expression and increased the expression level of PDE3B mRNA up to 3. adipocytes with cPA or T0070907 results in decreased PDE3B gene expression (Fig. 3A) . PDE3B protein was then quantified by Western blotting using anti-PDE3B antibody (Fig. 3B) . In treated cells with rosiglitazone, expression of PDE3B protein was increased to 1.9-fold compared to vehicle alone. This rise of PDE3B protein level was also suppressed by treatment with cPA or T0070907. Based on these data, we proposed that PDE3B might act through a PPARc dependent regulation.
cPA stimulates intracellular cAMP production
Mukai et al. reported that cPA elevates intracellular cAMP concentration in MM1 cell line [33, 34] . However, the mechanism by which PDE3B initiates activation of intracellular cAMP production by cPA is still unclear. To address this question, we examined the effects of cPA on the intracellular cAMP concentration in 3T3-L1 adipocytes. As shown in Fig. 3C , treatment of adipocytes with cPA significantly increased the amount of free glycerol. This is suggests that TG was hydrolyzed in adipocytes to FFA and glycerol through the lypolysis. We next examined the level of intracellular cAMP in 3T3-L1 adipocytes, and the cAMP level in 3T3-L1 adipocytes by cPA or ccPA (1 and 10 lV) was observed (Fig. 3D) . From these results, cPA is shown to influence the degradation of TG converting into free glycerol by inhibiting PDE3B expression, and subsequent increase of intracellular cAMP level is caused (Fig. 4) . These results suggest that cPA effects are associated with a decrease in the PPARc activation as well as a diminished expression of PDE3B. cAMP-regulated lipolytic reaction in adipocytes is the critical gateway for stored energy release in cells [31] . Our data show that, cPA stimulates lipolysis might, at least in part, be caused by cPA. Further experiments are required in order to dissect the cross talk between these molecules. However, these studies support the potential use of cPA and its derivative as a therapeutic compound for obesity and obesity-related diseases.
